On November 17, 2021 BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) ("BioVaxys" or "Company"), a clinical-stage immunotherapy company, reported that Company Co-Founder and Chief Medical Officer David Berd, MD, will present at the World Vaccine & Immunotherapy Congress West Coast 2021 taking place November 30-December 2, 2021 in San Diego (Press release, BioVaxys Technology, NOV 17, 2021, https://biovaxys.com/2021/11/17/biovaxys-co-founder-and-chief-medical-officer-david-berd-md-to-present-at-world-vaccine-immunotherapy-congress-west-coast-2021/ [SID1234595730]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Berd will discuss the role of immunotherapeutic vaccines in cancer, the potential of haptenized autologous tumor cell vaccines for treating a range of cancer types, and BioVaxys’ advancement of haptenized viral antigens as a platform for addressing SARS-CoV-2, SARS-CoV-1, and other sarbecoviruses.
Details of the presentation are as follows:
Title: Haptenized Vaccines for Viral Diseases & Cancer
When: December 1, 2021 @ 17:10
Where: Lowes Coronado Hotel, San Diego, CA
"BioVaxys is honored to be invited to speak at the World Vaccine & Immunotherapy Congress alongside a prestigious group of vaccine and immunology experts. We look forward to sharing how we are leveraging our haptenized protein platform to create autologous cancer immunotherapies synergistic with checkpoint inhibitors, as well as protein-based vaccines for infectious disease," said Dr. Berd.
A medical oncologist, Dr. Berd has a life-long record of clinical research in medical oncology and cancer immunotherapy. For more than 20 years, he was a professor of medicine at Thomas Jefferson University, where he conducted clinical research on melanoma vaccines. Over the course of his career, Dr. Berd has published more than 85 original papers in numerous medical journals in addition to myriad editorials, reviews, and abstracts. He has 10 issued cancer vaccines patents.